TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01593046
Drug: GSK1265744 LAP 200mg intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg maintenance dose given at months 2 - 4
Study: NCT01593046
Drug: GSK1265744 LAP 400mg intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg maintenance dose given at month 2 - 4
Study: NCT01593046
Drug: TMC278 LA 1200mg intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200mg Loading dose given at month 3
Study: NCT02852551
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01593046
Drug: GSK1265744 LAP 800mg intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800mg dose given quarterly (once every) 12 weeks
Study: NCT00546585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline for injection (0.9%); 0.5 ml volume sodium chloride injection. Subjects will receive 2 doses on Day 0 and Day 28.
Study: NCT03110198
Drug: hydrocortisone sodium succinate
Normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydrocortisone sodium succinate rectal administration at bedtime 100mg/100 ml, once daily
Study: NCT02568124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03101514
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 80-100mg/m2 was used every 3 weeks during radiotherapy.
Study: NCT04363437
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID Patients in this arm will receive usual care COVID19 treatment and will not receive colchine.
Study: NCT03030911
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The drug will be administered in both groups
Study: NCT02193256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02815293
Drug: AGN-195263
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of AGN-195263 will be instilled in each eye twice daily.
Study: NCT02815293
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of AGN-195263 vehicle (placebo) will be instilled in each eye twice daily.
Study: NCT02442180
Drug: steroid
Normalized name: Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral prednisolone 40mg qd or iv methylprednisolone 32 mg if oral medication is not tolerable
Study: NCT02442180
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: equivalent to G-CSF doses
Study: NCT04154956
Drug: SAR408701
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Concentrate for solution for intravenous infusion Route of administration: intravenous (IV) infusion
Study: NCT02902913
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg of Ibuprofen
Study: NCT02248792
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01597050
Drug: R932333
Approvals — FDA: no, EMA: no, PMDA: no
Description: R393233 6% (60 mg/g), bid
Study: NCT01597050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, bid
Study: NCT03229954
Drug: iron isomaltoside (Monofer) intravenous infusion
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational drug is a newest formulation of intravenous iron. The drug, iron isomaltoside (Monofer), will be infused one single high dose with infusion time more than 30 minutes (\< 1,000 mg) or 60 minutes (≥ 1,000 mg). The dosage is determined using the Ganzoni formula and divided when the calculated dose exceeds 20 mg/kg.~If the calculated dose exceeds 1,500 mg, the patient will be excluded from trial for patient safety.
Study: NCT01200069
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identically appearing placebo dose administered IV prior to ECT and subsequently on ECT treatments 2 and 3
Study: NCT01200069
Drug: ibuprofen intravenous
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT and subsequently on ECT treatments 2 and 3
Study: NCT01738295
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03659929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02895256
Drug: Any treatment for cluster headache
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01185197
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg/kg/day to be tapered over a period of 24 weeks at the discretion of the attending physician
Study: NCT01226030
Drug: M2ES 7.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2ES 7.5mg
Study: NCT01226030
Drug: M2ES 15mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2ES 15mg
Study: NCT01226030
Drug: M2ES 30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2ES 30mg
Study: NCT01226030
Drug: M2ES 60mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2ES 60mg
Study: NCT03975374
Drug: Tobramycin/dexamethasone opthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: To compare efficacy and safety in randomized patients recieving Tobradex versus Tobramycin/Dexamethasone opthamic Solution
Study: NCT03975374
Drug: Tobradex Opthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobradex Opthalmic Solution
Study: NCT01240148
Drug: AZD3161
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, intradermal injection
Study: NCT01240148
Drug: AZD3161 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01522625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, identical to TDF in appearance, once daily for 3years
Study: NCT01843296
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00735085
Drug: SLV334
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg SLV334 as a single dose
Study: NCT00735085
Drug: SLV334
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg SLV334 b.i.d. for one day
Study: NCT00735085
Drug: SLV334
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000mg SLV334 b.i.d. for one day
Study: NCT00735085
Drug: SLV334
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000mg SLV334 b.i.d. for three days
Study: NCT00735085
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLV334 Placebo arm
Study: NCT02207634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
Study: NCT02207634
Drug: Background Statin Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were required to be on a stable, high- to moderate-intensity statin background therapy consisting of an effective statin dose, ie, at least atorvastatin 20 mg daily or equivalent, and where locally approved, highly effective statin therapy (defined as at least atorvastatin 40 mg daily or equivalent) was recommended.
Study: NCT03032848
Drug: Estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: use of 1 gram per day
Study: NCT03596658
Drug: SHR9549
Approvals — FDA: no, EMA: no, PMDA: no
Description: If initial dosing of SHR9549 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose(MTD) is defined
Study: NCT04122040
Drug: Roxithromycin 300 MG
Normalized name: roxithromycin 300 MG
DrugBank: Roxithromycin (DB00778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin 300 mg oral per day
Study: NCT04122040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one table oral once dialy
Study: NCT00129389
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm A: FAC Arm B: FAC-wP
Study: NCT00129389
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm A: FAC Arm B: FAC-wP
Study: NCT00129389
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm A: FAC Arm B: FAC-wP
Study: NCT02202226
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02125201
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A neonate will recieve Fentanyl intranasal or intravenous 5 minutes before the procedure The nurse will check his pain scale If the pain scale will be more than 4 the neonate will recieve the second dose of Fentanyl
Study: NCT02501018
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) is defined as pharmacotherapy with approved drugs (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids).
Study: NCT02605915
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be administered at 60 mg/m\^2 every 2 weeks as an IV bolus over 3 to 5 minutes or as an infusion over 15 to 30 minutes.
Study: NCT02605915
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered at 600 mg/m\^2 on Day 1 of each 21 day cycle as an IV bolus over 3 to 5 minutes or as an infusion, in accordance with local policy.
Study: NCT02604407
Drug: SHP465 12.5mg capsules (one capsule daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one capsule daily
Study: NCT04611503
Drug: subretinal injection of rAAV.hPDE6A
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first 3 patients (C1) will receive the intermediate dose 1x1010 vg. After injection of the 3rd patient of C1, the DMC will give a go/no go decision. If 'nogo', a lower dose (5x109 vg) will be given to the next group of 3 patients (C2). The DMC will give a go/no go decision. In case of a go decision, 3 further patients (C3) will be treated with the same dose. In the case of a no-go decision, the next dose will be the minimal dose 1x109 vg. In case of a 'go' decision of the DMC after the third patient, the next 3 patients will receive a subretinal injection of vector at the highest dose 5x1010 vg. The DMC will give a go/no go decision after review of all safety data available at D30 of cohort 2. If safety data is considered favourably by the DMC, then 3further patients (cohort 3) will be treated with the same dose (5x1010 vg). Should any safety concerns arise, the last three patients (cohort 3) will receive the intermediate dose (1x1010 vg).
Study: NCT02278328
Drug: STX209 (15mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (15mg) intervention is the low dose
Study: NCT02278328
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The placebo intervention is the non-active placebo control dose
Study: NCT02278328
Drug: STX209 (30mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (30mg) intervention is the high dose
Study: NCT04623892
Drug: TQB2618 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2618 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2618 is diluted to 100 m with normal saline \[0.9% (w/v) sodium chloride solution\], and the infusion time is 60 ± 10 min.
Study: NCT02691325
Drug: Placebo ELLIPTA DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ELLIPTA DPI contains lactose.
Study: NCT04123405
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to acetylcysteine
Study: NCT04667624
Drug: LodineT
Approvals — FDA: no, EMA: no, PMDA: no
Description: •Manufactured by Hanlim Pharm. Co., Ltd, Seoul, Korea
Study: NCT00601887
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004338
Drug: zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01666678
Drug: BAY98-7111
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fasting conditions
Study: NCT01666678
Drug: Naproxen Sodium (Aleve, BAYH6689)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 x Naproxen Sodium 220 mg under fasting conditions
Study: NCT01666678
Drug: BAY98-7111
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fed conditions
Study: NCT00002704
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002704
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002704
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002704
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002704
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03875781
Drug: Radiochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: Active comparator~* Intervention Name : modified FOLFIRINOX followed by preoperative standardized radiochemotherapy (control arm)~* Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively.followed by preoperative radiochemotherapy with concurrent capecitabine 825 mg/m2/12h 5 days/week and intensity modulated radiation therapy using a simultaneous integrated boost technique with 45 Gy in 25 fractions in pelvic volume and 50 Gy in 25 fractions to the tumor.
Study: NCT02324582
Drug: Intravenous MK-3475/ Intravesical BCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles (each cycle is 21 days) of pembrolizumab will be given over 9 weeks in combination with BCG. BCG treatment will begin on Day 1 of cycle 3 of pembrolizumab.
Study: NCT00246324
Drug: Interferon beta 1a, oral doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients took intramuscular interferon beta 1a, 30 micrograms, for 3 months then added oral doxycycline, 100 daily with the interferon for 4 months.
Study: NCT02794285
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
Study: NCT01284452
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 50 ml intravenous every 6 hours for 7 days
Study: NCT01284452
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 50 mg intravenous every 6 hours for 7 days
Study: NCT02211417
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03645863
Drug: Iron supplement C
Normalized name: HERBAL IRON SUPPLEMENT CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT03645863
Drug: Iron supplement D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT02535689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00727103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be dispensed in color-coded capsules. Blue capsules will contain 0.5 mg glucose (placebo), red capsules will contain 1 mg glucose (placebo).
Study: NCT00676832
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solid capsule dosage form administered orally once daily.
Study: NCT01277211
Drug: ENG 120 µg + EE 15 µg intravaginal ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 cycles of ENG-EE (NuvaRing) vaginal ring use. Each cycle 28 days, with a 21-day active treatment period followed by 7-day ring-free period. One ring per cycle, each ring containing 11.7 mg ENG and 2.7 mg EE, and releasing on average 120 mcg/day of ENG and 15 mcg/day of EE.
Study: NCT01382888
Drug: Heparin 2,400 IU /ml Cutaneous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication twice daily. Patients will get adequate training before first administration.
Study: NCT00240279
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02074007
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerin ear drops (placebo) drops administered as needed for ear pain
Study: NCT01627678
Drug: Vacc-C5/GM-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
Study: NCT01627678
Drug: Vacc-C5/Alhydrogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
Study: NCT03206346
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, capsules daily for 5 days.
Study: NCT03899909
Drug: Placebo SAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral suspension
Study: NCT03899909
Drug: GLPG3121 MAD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GLPG3121 oral suspension, multiple ascending doses, daily for 13 days
Study: NCT03899909
Drug: Placebo MAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral suspension, daily for 13 days
Study: NCT01160328
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5g - 1% testosterone gel, daily x 7 weeks
Study: NCT04164290
Drug: Jiashen Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet
Study: NCT04164290
Drug: Jiashen Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets
Study: NCT04164290
Drug: Jiashen Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets
Study: NCT04164290
Drug: Jiashen Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 tablets
Study: NCT04164290
Drug: Jiashen Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 tablets
Study: NCT04164290
Drug: Jiashen Tablets Placebo
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet
Study: NCT04164290
Drug: Jiashen Tablets Placebo
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets
Study: NCT04164290
Drug: Jiashen Tablets Placebo
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets
Study: NCT04164290
Drug: Jiashen Tablets Placebo
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 tablets
Study: NCT04164290
Drug: Jiashen Tablets Placebo
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 tablets
Study: NCT04164290
Drug: Jiashen Tablets Placebo
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 tablets
Study: NCT02443740
Drug: BIIB118
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 10 mg, 100 mg, 400 mg, and placebo
Study: NCT02443740
Drug: BIIB118
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (Maximum Tolerated Dose) of BIIB118 as extemporaneously prepared solution/suspension
Study: NCT00489255
Drug: Tigan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule, 300mg three times daily
Study: NCT00489255
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule, three times daily
Study: NCT02982837
Drug: PEG-IFN & Nucleos(t)tide analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who will be randomized to receive 180 Mcg/ week as an add-on Pegylated Interferon therapy α-2 A with their ongoing NUCLEOTIDE analogues for 48 weeks.
Study: NCT03008382
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
Study: NCT02742883
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with diffuse intrinsic pontine glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT02546661
Drug: AZD4547
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4547 Monotherapy vs. MEDI4736 (durvalumab) + AZD4547 1:1 Randomization.